Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

Callum Baird Nattress, Rhianna O’Sullivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, María Ramos Zapatero, Ferran Cardoso Rodriguez, Xiao Qin, Ashley A. Campbell, Angeliki Kanouta, Vivian Li, Kerry Chester, John Anderson, Marta Barisa, Jonathan Fisher, Christopher J. TapeCancer 2025 · DOI

TL;DR

Engineered γδ T cells can overcome cancer's defenses by using multiple killing mechanisms (multimodal cytotoxicity). This approach allows them to effectively eliminate even chemoresistant cancer stem cells, a significant challenge for current cancer therapies.

What Problem Does This Paper Address?

Adoptive T-cell therapies, like CAR-T cells, have shown great promise against blood cancers, but their effectiveness against solid tumors is limited. A key reason for this is the complex and often immunosuppressive tumor microenvironment (TME) in solid tumors. Cancer cells can actively suppress T-cell activity, a phenomenon known as immunomodulation. Furthermore, solid tumors exhibit significant heterogeneity (intertumor heterogeneity, ITH), meaning different tumors, or even different parts of the same tumor, can have distinct characteristics and respond differently to treatment. This is further complicated by variability in T-cell products derived from different donors (interdonor heterogeneity, IDH).

This paper tackles the challenge of developing effective T-cell therapies for solid tumors by investigating γδ T cells, a different type of T cell with unique killing capabilities. Specifically, the authors aim to understand how γδ T cells can overcome cancer cell-induced immunomodulation and how their effectiveness is influenced by tumor heterogeneity and donor variability. They focus on colorectal cancer, a solid tumor where chemoresistance and heterogeneity are major clinical hurdles.

Methods

The core of this study is a technique called phenoscaping, which combines high-throughput perturbations with high-dimensional single-cell analysis. This allows researchers to systematically map the factors that regulate cellular behavior.

Key techniques employed include:

  • Thiol-reactive organoid barcoding in situ mass cytometry (TOBis MC): This is a novel method used to analyze a large number of parameters (posttranslational modification signaling, cell cycle, apoptosis, and immunophenotypes) at the single-cell level in complex 3D organoid cultures. It allows for the simultaneous measurement of many cellular features.
  • Patient-Derived Organoids (PDOs): These are 3D cultures derived directly from patient tumors, providing a more realistic model of tumor heterogeneity and the tumor microenvironment than traditional 2D cell lines.
  • Engineered γδ T cells (stIL15-γδ T cells): γδ T cells were genetically engineered to express a stabilized form of IL-15 (stIL15). IL-15 is a cytokine known to promote T-cell survival and function, and engineering cells to secrete it aims to enhance their persistence and cytotoxic potential, especially in the nutrient-poor TME.
  • CRISPR gene editing: Used to create B7-H3 knockout (KO) PDOs to specifically investigate the role of B7-H3 in antibody-dependent cellular cytotoxicity (ADCC).
  • Single-cell RNA sequencing (scRNA-seq): Used to analyze the stem cell characteristics (proliferative vs. chemoresistant) of the PDOs.
  • Earth Mover's Distance (EMD): A metric used to quantify the differences in cellular states and signaling networks between different experimental conditions.

Datasets

The study utilized:

  • Colorectal cancer patient-derived organoids (PDOs): Over 1,000 PDO cultures from various patients were used, representing intertumor heterogeneity.
  • γδ T cells from multiple healthy donors: Cells from seven different donors were used to assess interdonor heterogeneity.
  • A panel of colorectal cancer PDOs: Over 780 PDO-γδ T-cell cultures were analyzed to compare the effects of tumor heterogeneity and donor variability.

No new benchmark datasets were introduced; rather, existing PDO models were leveraged to create a complex experimental system.

Key Insights and Ideas

  • Multimodal killing is key: γδ T cells can kill cancer cells through antibody-independent cytotoxicity (AIC) and antibody-dependent cellular cytotoxicity (ADCC). The study highlights that combining these mechanisms is crucial for overcoming cancer's defenses.
  • Cancer fights back: Cancer cells don't passively receive T-cell attacks; they actively modulate γδ T-cell signaling and function, suppressing their cytotoxic potential, especially when T cells rely on a single killing mechanism (like AIC alone).
  • stIL15 is a powerful enhancer: Engineering γδ T cells to secrete stIL15 significantly improves their viability, expansion, and cytotoxic potential, particularly in challenging 3D environments without external support.
  • Tumor heterogeneity is dominant: The characteristics of the tumor (intertumor heterogeneity) have a stronger influence on γδ T-cell behavior and signaling than the origin of the T cells (interdonor heterogeneity).
  • Chemoresistant cells are vulnerable: Engineered γδ T cells can effectively kill even chemoresistant cancer stem cells (revCSCs), which are a major challenge for current therapies.

Key Results

  • Unmodified γδ T cells showed limited anti-tumor activity.
  • stIL15-engineered γδ T cells demonstrated significant cytotoxicity against PDOs via AIC.
  • Cancer cells reciprocally modulated stIL15-γδ T-cell signaling, reducing their cytotoxic potential when only AIC was used.
  • Adding an anti-B7-H3 antibody to engage ADCC, in combination with AIC, allowed stIL15-γδ T cells to overcome cancer cell immunomodulation and restore their signaling networks.
  • This multimodal killing strategy enabled stIL15-γδ T cells to kill chemoresistant revCSC-enriched colorectal cancer PDOs, a feat not achieved by standard chemotherapy.
  • The effectiveness of γδ T cells was more influenced by the specific PDO (tumor heterogeneity) than by the donor of the γδ T cells.

Limitations and Future Work

  • In vitro focus: While the study uses advanced 3D models, it is primarily an in vitro investigation. Further validation in in vivo models is necessary.
  • Specific antibody: The study focused on anti-B7-H3 mAb for ADCC. Exploring other antibody targets and combinations could broaden the applicability.
  • Donor variability: While stIL15 engineering aims for universal efficacy, some donor-specific variations in response were observed, suggesting further optimization might be needed for specific patient populations.
  • Future directions: The authors suggest exploring combinations of stIL15-γδ T cells with immune checkpoint inhibitors, as B7-H3 can also act as an immune checkpoint. They also highlight the potential of engineering γδ T cells for enhanced CD16 signaling and exploring other immune cell engagers to further boost multimodal cytotoxicity. The development of non-cleavable CD16 constructs and the selection of γδ T-cell donors with high-affinity Fc receptors are also promising avenues.

Summary updated

Abstract

Single-cell phenoscaping of more than 1,000 γδ T-cell and patient-derived organoid cultures shows that cancer cells suppress anticancer γδ T-cell cytotoxicity but γδ T cells can use multimodal killing to overcome immunomodulation.
BibTeX
@inproceedings{nattress2025phenoscaping,
  author = {Callum Baird Nattress and Rhianna O’Sullivan and Daniel Fowler and Colin Hutton and Petra Vlckova and Jahangir Sufi and Magdalena Buschhaus and Ewa Basiarz and María Ramos Zapatero and Ferran Cardoso Rodriguez and Xiao Qin and Ashley A. Campbell and Angeliki Kanouta and Vivian Li and Kerry Chester and John Anderson and Marta Barisa and Jonathan Fisher and Christopher J. Tape},
  title = {{Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation}},
  booktitle = {Cancer},
  year = {2025},
  doi = {10.1158/0008-5472.can-25-1890},
}
Figure